ALEXANDER LARSON: Open Payments
NPI 1679168223 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$658 in 27 payments from 16 companies in 2025. Trend: 2023 $420 · 2024 $801 · 2025 $658
Food & beverage: $658
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $199 |
| AstraZeneca Pharmaceuticals LP | 3 | $78 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| Dexcom, Inc. | 2 | $47 |
| Novo Nordisk Inc | 2 | $40 |
| ABBVIE INC. | 2 | $39 |
| Lilly USA, LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| PFIZER INC. | 1 | $19 |
Products named: FARXIGA, Dexcom G6 Transmitter, TRELEGY ELLIPTA, OTEZLA, REPATHA, TRINTELLIX, UBRELVY, Ozempic.
Industry payments across ID — which companies pay providers there.
